SILO Profile
Silo Pharma, Inc., a developmental stage biopharmaceutical company, is pioneering the integration of traditional therapeutics with cutting-edge psychedelic research. The company is dedicated to developing novel treatments for a range of underserved medical conditions, leveraging the potential of psychedelic compounds, such as psilocybin. This approach aims to address various mental health and neurological disorders, including depression, post-traumatic stress disorder (PTSD), Alzheimer’s disease, and Parkinson’s disease.
The company focuses on acquiring and developing intellectual property and technology rights from leading universities and research institutions. By collaborating with academic and scientific communities, Silo Pharma seeks to advance its research and therapeutic offerings in areas where traditional treatments have proven insufficient. The integration of psychedelic drugs into conventional therapeutic frameworks represents a significant innovation, potentially offering new solutions for rare and challenging diseases.
Silo Pharma’s research and development strategy involves evaluating the efficacy and safety of psychedelic compounds in clinical settings. The company’s work includes exploring the therapeutic benefits of these substances for conditions such as depression and various neurological disorders. This research is conducted with the aim of providing alternative or adjunctive treatments that could complement existing therapies and offer enhanced outcomes for patients.
Originally founded as Uppercut Brands, Inc., the company rebranded to Silo Pharma, Inc. in September 2020 to better reflect its focus on biopharmaceutical development. Incorporated in 2010 and headquartered in Englewood Cliffs, New Jersey, Silo Pharma is committed to advancing the field of psychedelic medicine and addressing critical gaps in current treatment options. The company's innovative approach positions it as a key player in the emerging field of psychedelic research and development.
|
